| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | THBD |
| Uniprot No | P07204 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 200-500aa |
| 氨基酸序列 | RGADFQALPVGSSAAVAPLGLQLMCTAPPGAVQGHWAREAPGAWDCSVENGGCEHACNAIPGAPRCQCPAGAALQADGRSCTASATQSCNDLCEHFCVPNPDQPGSYSCMCETGYRLAADQHRCEDVDDCILEPSPCPQRCVNTQGGFECHCYPNYDLVDGECVEPVDPCFRANCEYQCQPLNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTQASCECPEGYILDDGFICTDIDECENGGFCSGVCHNLPGTFECICGPDSALARHIGTDCDSGKVDGGDSGSGEPPPSPT |
| 预测分子量 | 47.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于THBD(Thrombomodulin)重组蛋白的参考文献示例(注：以下内容为示例，实际文献请通过学术数据库查询)：
---
1. **标题**：Recombinant thrombomodulin protects against sepsis by inhibiting coagulation and inflammation
**作者**：Conway EM, et al.
**摘要**：研究重组THBD蛋白在脓毒症小鼠模型中的作用，发现其通过激活蛋白C通路抑制凝血级联反应，并减少促炎因子释放，显著提高生存率。
2. **标题**：Structural and functional analysis of recombinant human thrombomodulin domains
**作者**：Wei Y, et al.
**摘要**：通过基因工程表达不同结构域的重组THBD蛋白，阐明其表皮生长因子样结构域(EGF-like domains)对凝血酶结合及蛋白C激活的关键作用。
3. **标题**：Recombinant soluble thrombomodulin suppresses arterial thrombosis in a primate model
**作者**：Suzuki K, et al.
**摘要**：在非人灵长类动物模型中，验证重组可溶性THBD蛋白通过调节凝血-抗凝平衡抑制动脉血栓形成，且无出血风险增加。
4. **标题**：High-yield production of recombinant thrombomodulin in mammalian cell culture
**作者**：Shi CS, et al.
**摘要**：优化哺乳动物细胞表达系统，实现重组THBD蛋白的高效分泌表达，并验证其生物活性与天然蛋白一致，为临床制备提供新方法。
---
建议通过PubMed、Google Scholar等平台检索关键词“recombinant thrombomodulin”或“soluble THBD”获取具体文献。
Thrombomodulin (THBD), a transmembrane glycoprotein predominantly expressed on vascular endothelial cells, plays a pivotal role in maintaining hemostatic balance and modulating inflammatory responses. It acts as a cofactor for thrombin-mediated activation of protein C, a natural anticoagulant that inhibits coagulation by degrading factors Va and VIIIa. Additionally, THBD binds thrombin to attenuate its procoagulant functions while enhancing its capacity to activate thrombin-activatable fibrinolysis inhibitor (TAFI), linking coagulation and fibrinolytic systems. Beyond coagulation, THBD exhibits anti-inflammatory properties by interacting with high-mobility group box 1 (HMGB1) and lipopolysaccharides (LPS), thereby mitigating endothelial dysfunction and sepsis-related damage.
Recombinant THBD (rTHBD) is engineered using biotechnological platforms (e.g., mammalian or insect cell systems) to mimic the functional domains of native THBD, particularly its extracellular lectin-like, EGF-like, and serine-rich regions. This recombinant form retains key biological activities, including protein C activation and anti-inflammatory signaling, while offering improved stability and scalability for therapeutic applications.
Clinically, rTHBD has shown promise in treating thrombotic disorders (e.g., disseminated intravascular coagulation) and inflammatory conditions like sepsis. Studies highlight its potential to reduce mortality in sepsis by modulating both coagulation cascades and cytokine storms. However, challenges persist in optimizing its pharmacokinetics and minimizing immunogenicity. Ongoing research explores fusion proteins and PEGylation strategies to enhance its efficacy, positioning rTHBD as a multifaceted therapeutic candidate in vascular and inflammatory pathologies.
×
